practical approaches to atrial fibrillation management

Practical Approaches to Atrial Fibrillation Management Answ ers to Your Everyday Questions H. Mark Guo, MD, FACC, FHRS Clinical Cardiac Electrophysiology Oregon Heart & Vascular Institute hguo@ Disclosure SYSTEMS OF

0 downloads 9 Views 3,63 MB Size Report
  1. Practical Approaches to Atrial Fibrillation Management Answ ers to Your Everyday Questions H. Mark Guo, MD, FACC, FHRS Clinical Cardiac Electrophysiology Oregon Heart & Vascular Institute hguo@

  2. Disclosure SYSTEMS OF CARE SYMPOSIUM 2015 Care of Your Patient in the Era of Population Health Hongsheng Mark Guo, MD, FACC, FHRS • I use free pens from all industrials. • I have no other financial relationships to disclose.

  3. Thursday 8 am: 63 yo man calls from MSP • In “AF” at least since Tuesday morning • Had breakfast in Indianapolis at 5:00am • Flight changed to 7:00pm to continue trip • Insists on not delaying trip any later • Previous episode in 5/2004 (metoprolol and propafenone) • Cardioversion scheduled 4:00pm

  4. ECG @ 9:40 am 4/26/07

  5. What would you do? A. Cardioverte and catch flight B. Cancel cardioversion, titrate BB, start coumadine, cardioverte after trip C. Cardioverte, start lovenox and coumadine, f/u w ith ACC D. Cancel cardioversion, titrate BB, start coumadine, ablation after 3-4 w eeks AC E. Start NOAC, TEE, cardioverte if no clot

  6. What is AF? • AF is the most common sustained arrhythmia. • Prevalence: 0.4% to 1% in general population, increasing w ith age to 12% for those > 75 yrs. • Stroke rate: < 1% to > 15% annually, depending on comorbid risk factors.

  7. Atrial Fibrillation Is Common

  8. Atrial Fibrillation Demographics by Age U.S. population Population with AF x 1000 x 1000 Population with 30,000 500 atrial fibrillation 400 U.S. population 20,000 300 200 10,000 100 0 0 <5 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75- 80- 85- 90- >95 9 14 19 24 29 34 39 44 49 54 59 64 69 74 79 84 89 94 Age, yr Adapted from Feinberg WM. Arch Intern Med. 1995;155:469-473.

  9. What is the Pathophysiology of AF? • AF may be triggered by a focal source of rapid atrial electrical depolarization, often in the pulmonary veins. • It is sustained by the presence of multiple reentrant w avelets or spiral w ave re- entrant circuits (rotors). Theories (Too Simple to be perfect) Wishes and dreams. Clueless!

  10. What causes my AF? • Acute and temporary causes (triggers) – alcohol intake (holiday heart) – surgery (particularly cardiac surgery) – MI, pericarditis, myocarditis, CHF – pulmonary embolism – hyperthyroidism. • Concurrent treatment of the underlying disorder and management of AF

  11. Other Causes of AF • Triggered by other arrhythmias – atrial tachycardia – atrial flutter – Wolff-Parkinson-White (WPW) syndrome – AV nodal reentrant tachycardia. • Associated w ith chronic disorders – sleep apnea – hypertension – obesity

  12. How to establish an accurate diagnosis of AF? • Symptoms maybe absent Not Reliable • “Irregularly irregular rhythm” • ECG – 12-lead – Ambulatory: Holter, Event monitor, ILR – Device interrogation • Should be distinguished from – atrial flutter, – multifocal atrial tachycardia – reentrant SVTs, such as AV nodal reentry; – sinus rhythm (SR) w ith multiple premature atrial complexes.

  13. Are all AFs the same? • Paroxysmal – terminates spontaneously w ithin 7 days of onset • Persistent – sustained > 7 days – longstanding persistent: c ontinuous AF > 12 months duration. • Permanent • Lone AF

  14. Are all AFs treated in the same w ay? • Hemodynamically unstable: – Immediate cardioversion, sedate if possible – Refractory, IV amiodarone, ibutilide, or procainamide. • Hemodynamically stable: – Cardioversion: new ly diagnosed, onset w ithin 48 hours – Rate control, anticoagulation if indicated – Cardioversion after 3-4 w eeks anticoagulation or no clot on TEE and therapeutic anticoagulation initiated.

  15. Case • 72 yo w oman, POD #1 (Ovarian mass removal), ECG show s AF HR 100-120 bpm, BP 158/66, R 18 • PMH: HTN, and CAD w ith LCx stented 5 yr ago • What w ould be your most appropriate next step: A. Cardioversion B. Aspirin C. Warfarin/NOAC D. Metoprolol E. TEE

  16. CASE • TEE is performed. Most likely result you predicted is: A. LAA thrombus B. Spontaneous echo contrast (smoke) in LA C. Clear LAA D. Annual stroke risk is 1-2% E. Annual stroke risk is 3-5% F. Annual stroke risk is 5-9%

  17. CHA 2 DS 2 -VASc Risk factor score C 1 Conge stive he ar t failur e / L V dysfunc tion H 1 Hype r te nsion Age ≥75y A 2 2 D 1 Diabe te s me llitus S 2 2 Str oke / T IA/ T E Vasc ular dise ase (pr ior myoc ar dial infar c tion, V 1 pe r iphe r al ar te r y dise ase , or aor tic plaque ) A 1 Age 65-74y Sc 1 Se x c ate gor y (ie fe male ge nde r ) 9 Maximum Sc or e maximum sc o r e is 9 sinc e age may c o ntr ubute 0, 1, o r 2 po ints L ip GY, e t a l., Che st 137, 263-272, 2010

  18. CHA 2 DS 2 -VASc – overall event rates Stroke and systemic embolism %/year 6 5 4 3 2 1 0 0-1 2 3 4 5 6 7 8-9 CHA 2 DS 2 -VASc No of patients 634 3408 5365 4378 2566 1185 451 125

  19. Marine JE. JAMA. 2007; 298(23): 2368-2778

  20. Cryoballoon

  21. Atrial Fibrillation Ablation: Success & Repeat Procedures • 50 – 70% success w ith a single procedure • Up to 50% w ill require a second procedure to achieve success • 50% w ill have early recurrence w ithin the first couple days to w eeks – 50% of these w ill resolve w ithin few w eeks and still have success

  22. Atrial Fibrillation Ablation: Long Term Outcome Free of antiarrhythmic drugs and free of arrhythmia symptoms at 6 months • Paroxysmal – 70 to 90% • Persistent (lasts > 7 days, up to 1 year) – 60 to 80% • Long standing persistent (> 1 year) – 50 to 70%

  23. Atrial Fibrillation Ablation: What are the risks? • Major: (overall risk < 1%) – Stroke (0.2%) – Heart attack (< 0.02%) – Atrial-esophageal fistula (rare – 0.02%) – Death (0.1%) • Intermediate: – Pulmonary vein narrow ing or stenosis (0.3%) – Bleeding around the heart or tamponade (1.0%) – Diaphragm paralysis (0.2%) – Need for a pacemaker (rare - < 0.02%) • Minor: – Groin site bleeding or hematoma (1 - 3%) – Infection (0.01%) * Second Worldw ide Survey on the Efficacy and Safety of Catheter Ablation for Atrial Fibrillation

  24. Atrioesophageal Fistula

  25. Catheter Ablation: How Is A Cure Delivered? Conventional AF Ablation • Mechanism? • Better understanding of mechanism – Microreentry – Multiple w avefronts • Fixed circuits or foci – No fixed circuit • Target: substrate – Triggers Atrial flutter • Target(s): AVNRT – Triggers? WPW – Drivers? Focal atrial tachycardia – Substrate? VT – Autonomic nerves?

  26. “ What Is EP?” 精致优雅 • Exquisiteness 精确 高雅 • Elegance • Precision 精巧 完美 • Delicacy • Perfection Cure Satisfaction

  27. “ What Is EP?” 粗糙 • Massiveness 邋遢 鲁莽 • Nastiness • Reckless • Excessiveness • Destructiveness 多余 毁坏 • Exquisiteness Deviating • Elegance • Precision • Delicacy • Perfection Cure Satisfaction

  28. When to offer a therapy as first-line? • Safety • Effectiveness • Need from patient

  29. AF Ablation Summary • AF ablation is an AF ablation, still. • There are many uncertainties. • More data is needed. • It is still too early to be offered to most patients as a first-line therapy. • Catheter ablation might be the right answ er for some patients.

  30. “Priority of Care” • Rate Control • Anticoagualtion • Rhythm Control

  31. 2/15/06, ER: 58 yo Man, Day Before EPS

  32. Before (12/23/05 08:47:00) After (02/16/06 15:50:55)

  33. What’s New in 2015? • Stroke risk assessment: CHA 2 DS 2 -VASc • New oral anticoagulants: – Dabigatran – Rivaroxaban – Apixaban – Edoxaban • Ablation: targeting substrates • Digoxin: associated w ith w orse outcome

  34. Stroke Prevention in 2015

  35. Digoxin is associated w ith bad outcomes

  36. Sinus Rhythm, Not AAD Use, Is Associated With Improved Survival The AFFIRM Investigators. Circulation. 2004;109:1509-1513.

  37. AF Ablation in 2015 Targeting Substrates

  38. Atrial Fibrosis Is Associated With AF Recurrence

  39. Summary • AF is common, w ith different clinical presentations. • AF is a complicated arrhythmia and our understanding regarding the exact mechanism remains limited. • Catheter ablation, although based on imperfect theory, may help selected patients. • AF is a manageable arrhythmia, and options are available for all patients to minimize risks for complications and to improve quality of life.

  40. References Questions? 541-600-4GUO hguo@

Recommend Documents

update on atrial fibrillation management disclosure
Update on atrial fibrillation

12/1/17 Update on atrial fibrillation management Disclosure Catheter

management and one year outcome of atrial fibrillation in
Management and one year outcome of

Management and one year outcome of atrial fibrillation in Middle Eastern

defining sub clinical atrial fibrillation and its
Defining Sub-Clinical Atrial

Defining Sub-Clinical Atrial Fibrillation and its management Jeff Healey MD,

atrial fibrillation afib what you need to know
Atrial Fibrillation (AFib): What You

Atrial Fibrillation (AFib): What You Need to Know 2018 Acknowledgements

atrial fibrillation
Atrial Fibrillation Saeed Oraii MD,

Catheter Ablation for Persistent Atrial Fibrillation Saeed Oraii MD,

safe consistent and effective management of atrial
Safe, consistent and effective

The day my heart skipped a beat Safe, consistent and effective

drugs used in the management of atrial fibrillation
Drugs Used In The Management Of Atrial

Drugs Used In The Management Of Atrial Fibrillation Dr Steve Murray

management of atrial fibrillation management of atrial
Management of Atrial Fibrillation

Management of Atrial Fibrillation Management of Atrial Fibrillation Nitish

atrial fibrillation reducing the risk of stroke
Atrial fibrillation Reducing The Risk

Atrial fibrillation Reducing The Risk of Stroke Bjrn Fredriksson Arrhythmia

advances in atrial fibrillation management and
Advances in Atrial Fibrillation

Advances in Atrial Fibrillation Management and Electrophysiology Joshua D.

venous reflux duplex exam
Venous Reflux Duplex Exam GWENDOLYN


ablation vs amiodarone for treatment of atrial
Ablation vs. Amiodarone for Treatment

Ablation vs. Amiodarone for Treatment of Atrial Fibrillation in Patients with

Atrophy Client: Karen Patterson

Exercise Device for child with Spinal Muscular Atrophy Client: Karen

overhand throwing overhand throwing mechanics mechanics
Overhand Throwing Overhand Throwing

Overhand Throwing Overhand Throwing Mechanics Mechanics and the

advanced sports taping

Types of Skin Reactions to Tape Physical Irritation ADVANCED SPORTS TAPING

the virginia department of corrections fairfax district
The Virginia Department of Corrections

The Virginia Department of Corrections Fairfax District 29 State Probation

what are my treatment options for af
What Are My Treatment Options for AF?

What Are My Treatment Options for AF? Mikhael El-Chami, MD FACC, FHRS Emory

a new amp exciting technology
A New & Exciting Technology

Visualase Therapy: A New & Exciting Technology Jessica Anne Wilden MD

radiofrequency ablation


magforce usa fighting cancer with nanotherm therapy


progress in fielding a zero focus shadowgraph system for
Progress in Fielding a Zero- Focus

Progress in Fielding a Zero- Focus Shadowgraph System for Ablation

adjuvant therapy of thyroid cancer
Adjuvant Therapy of Thyroid Cancer:

Adjuvant Therapy of Thyroid Cancer: rhTSH, RAI, EBRT and Targeted Therapeutics